NCT00217412View on ClinicalTrials.gov

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Childhood Acute Promyelocytic Leukemia (M3)Childhood Atypical Teratoid/Rhabdoid TumorChildhood Burkitt LymphomaChildhood Chronic Myelogenous LeukemiaChildhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaJuvenile Myelomonocytic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood MedulloblastomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent/Refractory Childhood Hodgkin LymphomaRelapsing Chronic Myelogenous LeukemiaUnspecified Childhood Solid Tumor, Protocol Specific
Interventions
DRUG

vorinostat

Given orally

DRUG

isotretinoin

Given orally

Trial Locations (1)

19104

Children's Oncology Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00217412 - Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia | Biotech Hunter | Biotech Hunter